This section explores the intricate relationship between PTEN loss and resistance to immune checkpoint inhibitors (ICIs) in cancer therapy, specifically focusing on how PTEN deficiency contributes to immune system suppression within the tumor microenvironment. This evidence concerns the gene PTEN and neoplasm.